63 results about "Diastolic function" patented technology

The invention provides an intelligent auxiliary evaluation system for right ventricular systole and diastole functions of echocardiography, and aims to solve the problems of low accuracy and efficiency in right ventricular function evaluation in the prior art. The system comprises an image acquisition unit, an image processing unit, a feature extraction unit, an intelligent evaluation unit and a result output unit, and through an intelligent algorithm, especially a deep learning network DL and a convolutional neural network CNN, a feature extraction result is obtained. Key indexes such as a two-dimensional right ventricular area change fraction 2D-FAC, a right ventricular ejection fraction RVEF and tricuspid valve ring plane contraction period displacement TAPSE are automatically calculated. The system also realizes accurate evaluation of the right ventricular function through a specific CNN structure and loss function design. The system can provide rapid, accurate and non-invasive right ventricular function evaluation in clinical practice, and is helpful for improving the diagnosis and treatment effects of cardiovascular diseases.

Methods, systems, and devices for evaluating function of a heart are provided. The methods can include use of one or more imaging modalities to assess diastolic function. The methods, systems, and devices can employ various features of a cardiac volume curve to assess cardiac function. The methods, systems, and devices can be used to guide diagnosis, therapy, and / or training for sick or well patients. Methods, systems, and devices for assessing likelihood of hospital readmission for a heart failure patient are also provided.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention discloses a coronary artery hemodynamic information prediction method, device and equipment, a medium and a product, and relates to the field of biomechanics, and the method comprises the steps: obtaining clinical data, and segmenting the clinical data to obtain a coronary artery three-dimensional model and a heart three-dimensional model; constructing a human body blood circulation system lumped parameter model; determining a personalized human body blood circulation system lumped parameter model of the patient after assignment; constructing a 0-3-dimensional myocardial mechanical coupling model; constructing a first database; obtaining personalized systolic function parameters and diastolic function parameters of the patient based on the first mapping network; constructing a blood vessel 0-3-dimensional coupling model; constructing a second database; obtaining personalized coronary flow field information of the patient based on a second mapping network; the personalized coronary flow field information comprises a pressure field, a velocity field and concentration polarization characteristics of low-density lipoprotein on a blood vessel wall surface. Through network architecture innovation, the bottleneck of the model in the aspects of efficiency and personalization is solved, and the diagnosis precision of the coronary heart disease is improved.

The invention relates to application of taurochenodeoxycholic acid in preparation of a medicine for preventing and treating hypertension. The key effect of the taurochenodeoxycholic acid in prevention and treatment of hypertension is found for the first time, that is, the taurochenodeoxycholic acid can significantly enhance the diastolic function of arteriole of a hypertensive patient, so that the effect of reducing blood pressure is achieved. Therefore, the invention provides a new application of taurochenodeoxycholic acid in preparation of the medicine for preventing and treating hypertension, a new medicine for preventing and treating hypertension is provided clinically, and the taurochenodeoxycholic acid has a good clinical application value and a wide application prospect. The taurochenodeoxycholic acid can be prepared into a medicine, a pharmaceutical composition, food, a health care product or a food additive by utilizing the key effect of the taurochenodeoxycholic acid in hypertension diseases, can be used for treating hypertension diseases including primary hypertension and salt-sensitive hypertension, and has important application value.

Provided are methods for identifying subjects at risk for reduced lifespan, age-associated cardiomyopathy, reduced cardiac function, heart failure, increased fibrosis of the myocardium, lung, and / or kidney; idiopathic pulmonary fibrosis (IPF); elevated left ventricular filling pressure (E / e′) indicative of diastolic dysfunction; and / or reduced cognitive function. In some embodiments, the methods include determining if the subject has mosaic loss of chromosome Y in blood (mLOY). Also provided are methods for preventing and / or treating diseases, disorders, and / or conditions associated with mLOY, which in some embodiments also include administering an anti-fibrotic therapy to the subject. Also provided are uses of inhibitors of TGFβ signaling or senolytic agents for prevention and / or treatment of diseases, disorders, and / or conditions associated with mLOY.

The invention relates to the technical field of traditional Chinese medicine compositions, and particularly discloses a composition for treating ejection fraction retention heart failure, which is technically characterized by comprising the following components in parts by weight: 8-10 parts of ginseng, 15-20 parts of salvia miltiorrhiza, 10-12 parts of radix polygonati officinalis, 10-15 parts of rhodiola rosea, 5-10 parts of pseudo-ginseng, 10-15 parts of turmeric, 15-17 parts of bighead atractylodes rhizome, 15-17 parts of poria cocos and 10-12 parts of centella asiatica. , 10-12 parts of herba lycopi and 10-12 parts of semen lepidii. Through systematic clinical observation and practice, the composition provided by the invention can obviously improve the clinical curative effect of a patient, improve traditional Chinese medicine syndromes, diastolic function indexes and exercise tolerance, and improve life quality; and the kit has a positive clinical application value for patients with clear diagnosis, accurate syndrome differentiation and good indication mastering.

The invention discloses application of Tongxinluo in preparation of a medicine capable of activating or enhancing a PERK-eIF2alpha-ATF4 signal channel. The medicine is used for treating or preventing diseases related to endoplasmic reticulum stress-mitochondrial autophagy axis dysfunction. The Tongxinluo regulates PINK1 / Parkin mediated mitochondrial autophagy by activating an eIF2alpha / ATF4 pathway, and can enhance selective elimination of damaged mitochondria while reducing the endoplasmic reticulum stress level of myocardial cells, so that heart remodeling is relieved, the diastolic function of the heart is improved, the symptom of the heart failure is relieved, and the progress of the heart failure is delayed.

Dihydroquinazolinone and azadihydroquinazolinone compounds are provided for use in the treatment of cardiac indications, such as hypertrophic cardiomyopathy and diastolic dysfunction.

The invention discloses an application of glycogen synthase kinase 3beta in preparation of antihypertensive drugs. The GSK3beta gene is inserted into a GV652 plasmid and is packaged into an adeno-associated virus, so that specific overexpression of the adeno-associated virus in vascular endothelial cells is realized, and the adeno-associated virus is used for preparing medicines for treating hypertension. It is found for the first time that overexpression of GSK3beta in endothelial cells can improve the endothelial dependent relaxation function and reduce blood pressure. Mechanism research shows that serine 9-site phosphorylation of GSK3beta can activate an AKT-eNOS signal channel and promote release of nitric oxide, so that the endothelial function is improved, and the antihypertensive effect is achieved. Furthermore, glycine can promote phosphorylation of the GSK3beta Ser9 site, and AKT-eNOS signal activation and NO generation are enhanced. The invention provides a novel anti-hypertension gene therapy strategy for regulating and controlling an endothelial function based on a GSK3beta gene.

Disclosed is a cardiac diastolic function assessment method applicable to the field of cardiac monitoring. The method comprises: acquiring vibration information of the thoracic cavity body surface of an object in a noninvasive manner; preprocessing the vibration information to generate hemodynamic-related information; determining a target wave group on the basis of the hemodynamic-related information; determining the highest peak on the target wave group, determining a rising edge amplitude before the highest peak as a first characteristic value, and determining, as a second characteristic value, an amplitude between the highest peak and the subsequent lowest valley; and generating an indicating parameter on the basis of the first characteristic value and the second characteristic value, and assessing a cardiac diastolic function of the object on the basis of the indicating parameter.

The invention discloses a millimeter wave radar heart failure diagnosis system based on a CNN and LSTM ordinal regression hybrid model, and the system comprises a radar signal processing module which is used for obtaining a radar signal and forming a slow time-distance complex matrix; the physical sign signal extraction module is used for obtaining a physical sign time sequence signal from the complex matrix; the heartbeat waveform separation module is used for generating a filtering interval according to the heart rate and extracting a heartbeat vibration waveform; the deep feature learning module is used for constructing a feature extraction network for the heartbeat vibration waveform and outputting continuous score prediction; and the ordinal regression diagnosis module is used for establishing a learnable threshold value based on continuous score prediction and generating an ejection function and diastolic function grading result. Accurate modeling of millimeter wave radar non-contact heart failure grading diagnosis is achieved, and heart function evaluation convenience and evaluation accuracy are improved.

High-throughput screening (HTS) assays described herein rely on structural alterations triggered by cTnI phosphorylation during beta-adrenergic stimulation. These HTS assays may be used to pinpointsmall molecules that emulate phosphorylation effects, amplifying lusitropy by accelerating calcium dissociation from thin filaments. With a focus on addressing diastolic dysfunction, especially in conditions like HCM, the aim is to determine compounds tailored to modulate diastolic performance.

Provided are methods for treating hypertrophic cardiomyopathy and diastolic dysfunction.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

A method (100) for classifying a patient's diastolic function, comprising: (i) receiving (120), from an ultrasound device (280), a plurality of 2D echocardiographic images of the patient's heart; (ii) analyzing (150), by a trained diastolic function prediction algorithm, the plurality of 2D echocardiographic images of the patient's heart to estimate left ventricular end-diastolic pressure (LVEDP); (iii) classifying (160) the patient's diastolic function as normal or abnormal based on the estimated LVEDP; and (iv) providing (170), to a user via a user interface, an indication of the patient's diastolic function as normal or abnormal.

The invention provides application of sedum spectabile total flavonoids in preparation of a medicine for treating pathological cardiac hypertrophy. The sedum spectabile total flavone can inhibit abnormal hypertrophy of cardiac muscle cells, improve arrangement disorder and fibrosis of the cardiac muscle cells, relieve thickening of ventricular walls, improve the diastolic function, delay or reverse pathological cardiac hypertrophy and relieve mitochondrial dysfunction in cardiac muscle tissue with cardiac hypertrophy.

The invention provides application of SRSF1 in preparation of a medicine for preventing and / or treating ejection fraction reserved heart failure, and belongs to the technical field of biological medicine. The invention determines that the SRSF1 can be used as a key target for preparation of heart failure related medicines for preventing and / or treating ejection fraction retention. Animal model construction and cellular level experiments prove that SRSF1 participates in regulation of the pathological process of the disease. Experiments of constructing a model in an SRSF1 endothelial cell specific knockout mouse show that by inhibiting SRSF1 expression, symptoms such as diastolic dysfunction and hypertension can be improved, pulmonary edema can be relieved, and myocardial fibrosis and reconstitution can be inhibited. The abnormal glucose and lipid metabolism can be improved, and the endothelial-mesenchymal transition process can be inhibited. The invention opens up a new path for new drug screening, provides a new target and method for treatment of ejection fraction reserved heart failure, and has important medical significance and value.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

A method (100) for classifying a diastolic function of a patient, comprising: (i) receiving (120) a plurality of 2D echocardiography images of a heart of the patient from an ultrasound device (280); (ii) analyzing (150) the plurality of 2D echocardiography images of the heart of the patient by a trained diastolic function prediction algorithm to estimate a left ventricular end diastolic pressure (LVEDP); (iii) classifying (160) the diastolic function of the patient as normal or abnormal based on the estimated LVEDP; and (iv) providing (170) to a user via a user interface an indication that the patient's diastolic function is normal or abnormal.

The application discloses a millimeter wave radar heart failure diagnosis system based on a CNN and LSTM ordinal regression hybrid model, and comprises the following modules: a radar signal processing module, which is used for acquiring radar signals and forming a slow time-distance complex matrix; a vital sign signal extraction module, which is used for obtaining a vital sign time sequence signal from the complex matrix; a heartbeat waveform separation module, which is used for generating a filtering interval according to a heart rate and extracting a heartbeat vibration waveform; a deep feature learning module, which is used for constructing a feature extraction network for the heartbeat vibration waveform and outputting a continuous score prediction; and an ordinal regression diagnosis module, which is used for establishing a learnable threshold based on the continuous score prediction and generating an ejection function and diastolic function grading result. The application realizes accurate modeling of non-contact heart failure grading diagnosis of the millimeter wave radar, and improves the convenience and accuracy of heart function evaluation.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

A cardiac diastolic function assessment method, for use in the field of cardiac monitoring. The method comprises: noninvasively acquiring vibration information of the thoracic body surface of a subject; preprocessing the vibration information to generate hemodynamics-related information; determining a first parameter and a second parameter on the basis of the hemodynamics-related information; generating an indicating parameter on the basis of the first parameter and of the second parameter, and assessing the cardiac diastolic function of the subject on the basis of the indicating parameter.

The invention belongs to the field of biological medicine, and particularly relates to application of acid glycoprotein ORM in preparation of anti-aging drugs, it is found that ORM protein is closely related to occurrence and development of aging, and on a cell model, exogenous ORM can remarkably improve cell aging induced by D-galactose and Etopside and cell aging induced by angiotensin II; on an animal model, the myocardial cell overexpression ORM1 can significantly improve the diastolic dysfunction of the heart of an old mouse, and in addition, the acid glycoprotein ORM is an endogenous protein of an organism, so that the safety of the acid glycoprotein ORM as a medicine is very high.

The present invention provides a crystalline form of (6S, 7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5, 6, 7, 8-tetrahydropyrido [2, 3-d] pyrimidine-2, 4 (1H, 3H)-dione ("Compound I"). Related pharmaceutical compositions, methods of preparation, and methods of treatment of hypertrophic cardiomyopathy (HCM), ejection fraction retention heart failure (HFpEF), diastolic dysfunction, left ventricular hypertrophy, and other heart diseases are also provided.

The present invention provides a pharmaceutical composition for treating heart failure with diastolic dysfunction, comprising a retinoid as an active ingredient. The heart failure with diastolic dysfunction may be heart failure with preserved left ventricular ejection fraction, heart failure with mid-range left ventricular ejection fraction, or heart failure with reduced left ventricular ejection fraction.

The invention discloses an application of a composition of a CD36 inhibitor and a PDK4 inhibitor in preparation of a medicine for treating HFpEF, and the CD36 inhibitor and the PDK4 inhibitor are combined for use and are used for cooperatively regulating and controlling myocardial metabolism reprogramming so as to treat the HFpEF. Through combined application of the CD36 inhibitor and the PDK4 inhibitor, the effects of the combined scheme on a plurality of key indexes such as improvement of the heart diastolic function of an HFpEF mouse, improvement of exercise tolerance, reversal of cardiac hypertrophy, reduction of pulmonary congestion and myocardial fibrosis and the like are remarkably superior to those of any single-drug treatment group of SSO or DCA, and synergistic treatment is achieved.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a modified Zhenwu decoction traditional Chinese medicine compound and application thereof. The traditional Chinese medicine compound of the modified true Wu decoction is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix aconiti lateralis praeparata slices, 6 to 18 parts of sun-dried ginseng, 10 to 30 parts of poria cocos, 8 to 24 parts of raw rhizoma atractylodis macrocephalae, 10 to 30 parts of radix paeoniae alba, 20 to 60 parts of pubescent holly root and 4 to 12 parts of rhodiola rosea. Clinical observation finds that the flavored Zhenwu decoction is an effective drug for resisting HFpEF, and can reverse cardiac hypertrophy of HFpEF mice, relieve pulmonary edema conditions, remarkably improve the diastolic function, improve HFpEF cardiac hypertrophy, improve cardiac diastolic dysfunction, improve myocardial injury and collagen deposition and improve myocardial cell mitochondrial injury.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.